Insights

Brea Lipe, MD, and Peter Forsberg, MD, discuss updates in the treatment of R/R multiple myeloma, and present two hypothetical patient profiles to show how recent data can be incorporated into clinical practice.

Dr Shaji Kumar and Dr Jonathan Kaufman discuss the evolving role of biomarkers in multiple myeloma.

Mark Pegram, MD, and Lee Schwartzberg, MD, FACP, have a discussion on the management of early-stage hormone-receptor-positive breast cancer and the tools available to help inform treatment decisions.

Expert oncologists center discussion on a clinical scenario to highlight optimal treatment strategies in metastatic triple-negative breast cancer.

Two experts in the management of extensive-stage small cell lung cancer provide an overview of chemotherapy-induced myelosuppression and share key insights into the myeloprotective benefit of the CDK4/6 inhibitor trilaciclib.

Dr Daniel Pollyea comments on the potential use of tamibarotene in patients that are newly diagnosed with acute myeloid leukemia (AML).

Dr Gustavo Rivero discusses how and where tamibarotene might fit into the treatment landscape for patients with higher-risk myelodysplastic syndrome (MDS).

Jennifer Atlas, MD, and Shahab Babakoohi, MD, discuss advances in the treatment of patients with basal cell carcinoma and their treatment approaches to clinical scenarios based on updated data.

An expert oncologist and pathologist discuss molecular testing in metastatic colorectal cancer and the current and upcoming options for HER2-targeted therapies.

Expert perspectives on recent evolutions with CDK4/6 inhibitors in the HR+, HER2- metastatic breast cancer treatment landscape.

Expert provides an overview of esophageal squamous cell carcinoma (ESCC), discusses several key updates to the treatment landscape, and elucidates how clinicians can improve patient outcomes by applying data from the treatment algorithm.

Richard Stone, MD, and Eunice Wang, MD, discuss recent advances in the treatment of newly-diagnosed acute myeloid leukemia and its impact on clinical practice.

Centering discussion on real-world patient scenarios, expert hematologist-oncologists review recent treatment advances in multiple myeloma with a focus on bispecifics and their impact on clinical practice.

Experts share insight on the evolving treatment armamentarium for myeloproliferative neoplasms. 

Dr. Michael Atkins and Dr. Evan Lipson discuss the state of metastatic melanoma, contemporary and emerging treatment strategies, and break down a specific patient profile. Their conversation touches on the pros and cons of different treatment strategies for newly diagnosed patients as well as second- and third-line treatment strategies. Dr. Atkins and Dr. Lipson also take time to provide their personal experiences, preferences, and thoughts on prospects involving the treatment and management of metastatic melanoma.

Experts in the field of differentiated thyroid cancer highlight recent advances in treatment by reviewing two real-world patient scenarios.

Expert oncologists share updates on the testing and treatment of molecular alterations in advanced non-small cell lung cancer.

Shared insight on the evolving treatment armamentarium for metastatic CRPC and how expert physicians are optimizing care.

A discussion on recent advances in the treatment of advanced renal cell carcinoma and their impact on clinical practice, illustrated by real-world patient profiles.

Expert perspectives on historical and novel treatment strategies for patients diagnosed with chronic graft-versus-host disease.